Viking Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 7, 2024
VKTX$28.99+8.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
The information required by this item will be contained in the Proxy Statement, which we expect to file not later than 120 days after the end of our year ended December 31, 2023, and is incorporated in this report by reference.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.